Transmission-Blocking Vaccines

2002 ◽  
pp. 287-307 ◽  
Author(s):  
D.C. Kaslow
Keyword(s):  
Transmission Blocking ◽  
Transmission Blocking Vaccines

Malaria transmission-blocking vaccines: wheat germ cell-free technology can accelerate vaccine development

2019 ◽  
Vol 18 (10) ◽  
pp. 1017-1027
Author(s):  
Kazutoyo Miura ◽  
Mayumi Tachibana ◽  
Eizo Takashima ◽  
Masayuki Morita ◽  
Bernard N. Kanoi ◽  
...  
Keyword(s):  
Germ Cell ◽  
Malaria Transmission ◽  
Wheat Germ ◽  
Vaccine Development ◽  
Transmission Blocking ◽  
Transmission Blocking Vaccines

scholarly journals Plasmodium P25 and P28 Surface Proteins: Potential Transmission-Blocking Vaccines

2007 ◽  
Vol 6 (8) ◽  
pp. 1260-1265 ◽  
Author(s):  
Ajay K. Saxena ◽  
Yimin Wu ◽  
David N. Garboczi
Keyword(s):  
Surface Proteins ◽  
Transmission Blocking ◽  
Transmission Blocking Vaccines

scholarly journals Transmission-Blocking Preventive Measures for Infectious Diseases: Altruism, Solidarity, and the Common Good

2021 ◽  
Author(s):  
Laine Garber ◽  
Joseph M. Vinetz
Keyword(s):  
Public Health ◽  
Common Good ◽  
Preventive Measures ◽  
Public Attention ◽  
Transmission Blocking ◽  
Contagious Diseases ◽  
Central Tenet ◽  
Health Advice ◽  
The Common ◽  
Transmission Blocking Vaccines

Aiming to prevent the spread of contagious diseases has long been a central tenet of public health. In the present time, divisive political responses to mask wearing to prevent SARS-CoV-2 transmission have competed with sound public health advice for public attention. Here, we draw parallels in terms of individualism versus societal solidarity between the slow and ponderous development of transmission-blocking vaccines for malaria and advocacy for mask wearing to prevent COVID-19.

scholarly journals Management strategies in a malaria model combining human and transmission-blocking vaccines

2017 ◽  
Vol 22 (3) ◽  
pp. 977-1000 ◽  
Author(s):  
Jemal Mohammed-Awel ◽  
◽  
Ruijun Zhao ◽  
Eric Numfor ◽  
Suzanne Lenhart ◽  
...  
Keyword(s):  
Management Strategies ◽  
Transmission Blocking ◽  
Model Combining ◽  
Malaria Model ◽  
Transmission Blocking Vaccines

scholarly journals Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to P. falciparum Transmission-Blocking Candidate Pfs25 in Humans

2021 ◽  
Vol 12 ◽  
Author(s):  
Marija Zaric ◽  
Arianna Marini ◽  
Carolyn M. Nielsen ◽  
Gaurav Gupta ◽  
David Mekhaiel ◽  
...  
Keyword(s):  
T Cell ◽  
Viral Vectors ◽  
Transmission Blocking ◽  
Peptide Epitopes ◽  
Cell Responses ◽  
Follicular Helper ◽  
Specific Memory ◽  
Modified Vaccinia Virus Ankara ◽  
Specific Igg ◽  
Transmission Blocking Vaccines

Plasmodium falciparum transmission-blocking vaccines (TBVs) targeting the Pfs25 antigen have shown promise in mice but the same efficacy has never been achieved in humans. We have previously published pre-clinical data related to a TBV candidate Pfs25-IMX313 encoded in viral vectors which was very promising and hence progressed to human clinical trials. The results from the clinical trial of this vaccine were very modest. Here we unravel why, contrary to mice, this vaccine has failed to induce robust antibody (Ab) titres in humans to elicit transmission-blocking activity. We examined Pfs25-specific B cell and T follicular helper (Tfh) cell responses in mice and humans after vaccination with Pfs25-IMX313 encoded by replication-deficient chimpanzee adenovirus serotype 63 (ChAd63) and the attenuated orthopoxvirus modified vaccinia virus Ankara (MVA) delivered in the heterologous prime-boost regimen via intramuscular route. We found that after vaccination, the Pfs25-IMX313 was immunologically suboptimal in humans compared to mice in terms of serum Ab production and antigen-specific B, CD4+ and Tfh cell responses. We identified that the key determinant for the poor anti-Pfs25 Ab formation in humans was the lack of CD4+ T cell recognition of Pfs25-IMX313 derived peptide epitopes. This is supported by correlations established between the ratio of proliferated antigen-specific CD4+/Tfh-like T cells, CXCL13 sera levels, and the corresponding numbers of circulating Pfs25-specific memory B cells, that consequently reflected on antigen-specific IgG sera levels. These correlations can inform the design of next-generation Pfs25-based vaccines for robust and durable blocking of malaria transmission.

Sign in / Sign up

Export Citation Format

Share Document